Physiomics shares rose 10.5% on Dec. 15, 2025, after winning an £116K–£169K contract to support a 2027 rheumatoid arthritis drug study.

Physiomics Plc shares rose 10.5% to 0.29p on December 15, 2025, after securing a follow-on contract worth £116,000–£169,000 to support a phase-two clinical study for a rheumatoid arthritis drug, building on prior pharmacokinetic modeling work. The project, set to begin in 2027, will run for about six months. Other market updates included Chariot Ltd finalizing financing for two South African wind projects, Helium One advancing its Colorado production facility, and Alusid raising £500,000 ahead of an AIM listing. The FTSE 100 rose on gains in mining and media stocks, while defence shares lagged.